Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats

著者	Khemawoot Phisit, Yokogawa Koichi, Shimada Tsutomu, Miyamoto Kenichi
journal or publication title	Biochemical Pharmacology
volume	73
number	1
page range	155-162
year	2007-01-01
URL	http://hdl.handle.net/2297/3444

doi: <https://doi.org/10.1016/j.bcp.2006.09.006>

available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/biochempharm

Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats

Phisit Khemawoot, Koichi Yokogawa, Tsutomu Shimada, Ken-ichi Miyamoto*

Department of Medicinal Informatics, Division of Cardiovascular Medicine, Graduate School of Medical Science, Kanazawa University, Japan

ARTICLE INFO

Article history:

Received 8 August 2006

Accepted 7 September 2006

Keywords:

Obesity

CYP2E1

Chlorzoxazone

Zucker rat

Abbreviations:

6OHCZX, 6-hydroxychlorzoxazone

6OHCZX-G, glucuronidated

6-hydroxychlorzoxazone

6OHCZX-T, total

6-hydroxychlorzoxazone

AST, aspartate aminotransferase

CYP, cytochrome P450

CZX, chlorzoxazone

CZX-G, glucuronidated

chlorzoxazone

PNP, p-nitrophenol

UGT, UDP-glucuronosyltransferase

ABSTRACT

This study was designed to investigate the induction of CYP2E1 in obese Zucker rats and its effect on the disposition kinetics of chlorzoxazone (CZX). CZX 20 mg/kg was administered to three groups of rats: normal Zucker rats fed a normal diet (ND), normal Zucker rats fed a high-fat diet (HF), and genetically obese Zucker rats fed a normal diet (OB). The values of the area under the plasma concentration–time curve from 0 to ∞ (AUC_{∞}) of CZX were in the order of ND > HF > OB rats. The AUC_{∞} values of total 6-hydroxychlorzoxazone (6OHCZX-T), which is considered to be a CYP2E1 metabolic marker, were in the opposite order. The values of the AUC_{∞} ratio (6OHCZX-T/CZX) in ND, HF and OB rats were approximately 0.2, 0.3 and 0.4, respectively. The CZX concentration in fat was much higher than the concentrations in plasma, liver and kidney in all groups. Induction of CYP2E1 protein was greater in both liver and fat of OB rats than in those of HF rats. Microsomal activity of CYP2E1 in liver and fat was also in the order of OB > HF > NM rats. These results suggest that CYP2E1 may be induced in liver and fat of obese patients, thereby potentially altering the disposition kinetics of not only CZX, but also other lipophilic drugs metabolized by CYP2E1.

© 2006 Published by Elsevier Inc.

1. Introduction

An increasingly sedentary lifestyle, together with a preference for refined foods containing high levels of meat and saturated fat, has resulted in a drastic increase in the incidence of metabolic abnormalities, obesity, and hypercholesterolemia,

which are associated with premature mortality [1,2]. Therefore, animal models, such as genetically obese Zucker (*fa/fa*) rats, have been developed to study the mechanisms of physiological changes related to obesity. The Zucker (*fa/fa*) rat does not develop leptin receptors, resulting in impaired regulation of food intake and impaired energy homeostasis

* Corresponding author at: Department of Hospital Pharmacy, School of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan. Tel.: +81 76 265 2045; fax: +81 76 234 4280.

E-mail address: miyaken@pharmacy.m.kanazawa-u.ac.jp (K.-i. Miyamoto).

0006-2952/\$ – see front matter © 2006 Published by Elsevier Inc.

doi:10.1016/j.bcp.2006.09.006

[3,4]. The overfed normal rat can also mimic physiological aspects of severe obesity in humans, such as hypercholesterolemia, hyperinsulinemia, etc. [5,6].

Changes in physiological status, such as obesity and hypercholesterolemia, can modulate the metabolic activity of CYP2E1 [7–9]. Interestingly, CYP2E1 is a ubiquitous enzyme that is distributed in various organs of animals, but obesity-related increase of CYP2E1 activity is well documented only in liver. There are several reports that the hydroxylation of chlorzoxazone (CZX) can be used as an indicator of CYP2E1 activity both in vivo and in vitro [10,11]. CZX is a muscle relaxant that primarily undergoes hydroxylation, catalyzed mainly by CYP2E1, to 6-hydroxychlorzoxazone (6OHCZX), which is rapidly glucuronidated and excreted in urine [12,13]. CZX is lipophilic [14], and so may be a suitable probe to examine the activity of CYP2E1 in various tissues of obese animals.

This study was therefore designed to examine the induction of CYP2E1 in genetically obese Zucker rats fed a normal diet (OB) and its effect on the disposition kinetics of CZX and its metabolite 6OHCZX in liver, kidney and fat, compared with those in normal Zucker rats fed a high-fat diet (HF) and normal Zucker rats fed a normal diet (ND).

2. Materials and methods

2.1. Materials

CZX and 6OHCZX were purchased from Sigma–Aldrich Inc. (St. Louis, MO). High-fat diet (LABO H Standard[®]) and normal diet (LABO MR Stock[®]) were purchased from Nosan Corp. (Yokohama, Japan). The high-fat diet contained 8.6% (w/w) fat (total energy 346.7 kcal/100 g), while the normal diet contained 4.1% (w/w) fat (total energy 259.2 kcal/100 g).

2.2. Animal treatment

Male 8-week-old Zucker (+/+) rats and genetically obese Zucker (*fa/fa*) rats were purchased from Japan SLC Inc. (Toyama, Japan). The rats were divided into three groups: normal Zucker (+/+) rats fed with normal diet (ND rats), normal Zucker (+/+) rats fed with high-fat diet (HF rats) and genetically obese Zucker (*fa/fa*) rats fed with normal diet (OB rats). The animals were housed for 3 months in a climate- and light-controlled environment with free access to water and the designated food. All animal procedures were in accordance with the standards set forth in the guidelines for the care and use of laboratory animals at the Takara-machi Campus of Kanazawa University.

2.3. Disposition kinetic of CZX

CZX (20 mg) was dissolved in 400 μ l of 0.5N NaOH and diluted with 600 μ l of normal saline solution (20 mg/ml). This solution was administered to rats at a dose of 20 mg/kg by i.v. administration over 2 min via a lateral tail vein. Then, approximately 0.2–0.5 ml of blood was collected from the tail vein on the other side at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, and 8 h after completion of the administration of CZX. The blood was centrifuged at 3000 $\times$ g for 10 min, and the plasma was

collected. Some rats were killed by decapitation at 4 h after CZX administration, and the liver, kidney and abdominal fat were quickly excised, rinsed well with ice-cold saline, blotted dry, and weighed. Each tissue sample was homogenized with normal saline and stored at –80 °C until analysis.

2.4. Sample preparation

The concentrations of CZX and 6OHCZX in biological samples were analyzed as unchanged and glucuronidated fractions. The assay of glucuronidated CZX and 6OHCZX was performed according to Frye and Stiff [15] with slight modifications. Briefly, a 100 μ l sample of plasma or tissue homogenate was added to 300 μ l of 0.2 M phosphate buffer (pH 6.5) containing 500 units of β -glucuronidase. The mixture was incubated at 37 °C with shaking for 2 h, and then the reaction was stopped by adding 100 μ l of acetonitrile containing phenacetin (1 μ g) as an internal standard for HPLC analysis.

2.5. HPLC assay of CZX and 6OHCZX

To a 100 μ l of sample solution was added 5 ml of diethyl ether, then the mixture was shaken vigorously for 10 min, and centrifuged at 3000 $\times$ g for 10 min. The ether layer was transferred to another tube for evaporation in a vacuum centrifugal concentrator. In the case of adipose tissue, reverse phase extraction from the case of homogenated samples was done by adding 0.5N NaOH to the samples and mixing. The aqueous phase was collected and titrated with an equal amount of 0.5N HCl. Next, diethyl ether (5 ml) was added to extract CZX and 6OHCZX from aqueous phase, and the organic solution was further processed as described above.

The residue from evaporation was dissolved in 200 μ l of the mobile phase, and a 50 μ l aliquot was injected into an HPLC system (LC-9A, Shimadzu Co. Ltd., Kyoto, Japan) equipped with a CAPCELL PAK C18 column, 1.5 mm i.d. $\times$ 150 mm (Shiseido Co. Ltd., Tokyo, Japan). The mobile phase consisted of 25% (v/v) acetonitrile in 50 mM KH₂PO₄ (pH 4.0), pumped at a rate of 0.1 ml/min. The absorbance was detected at wavelengths of 295 and 287 nm for 6OHCZX and CZX, respectively [14,16]. The retention times of 6OHCZX, phenacetin and CZX were approximately 5, 12 and 20 min, respectively. Linear calibration curves ($r > 0.999$) were obtained for both compounds in plasma over the concentration range from 1 to 150 μ g/ml. The limits of detection were estimated to be 0.25 μ g/ml for both CZX and 6OHCZX.

2.6. Reverse transcriptase polymerase chain reaction (RT-PCR) assay

Total RNA was isolated from liver, kidney and fat with Isogen (Nippon Gene Co. Ltd., Toyama, Japan). Each RNA sample (1 μ g) was reversed-transcribed at 37 °C for 2 h, and the cDNA was amplified with a Peltier Thermal Cycler PTC-100 (Bio-Rad Laboratories Inc., Hercules, CA). The numbers of amplification cycles were 30 for fat cDNA and 25 for cDNAs from other tissues. PCR products were evaluated by electrophoresis on 2% (w/v) agarose gel stained with ethidium bromide, and photographed under UV trans-illumination. The product size was estimated by comparison with a 100 bp DNA ladder

(Takara Bio Inc., Shiga, Japan). Control reactions to verify the absence of contaminants and genomic DNA were routinely performed. Primers used for rat CYP2E1 were 5'-CTG ATT GGC TCG CGA CCC TGC-3' and 3'-GAA CAG CTC GGC CAA AGT CAC-5' (456 bp), and those for rat β -actin were 5'-TTC TAC AAT GAG GTG CGT GTG GC-3' and 3'-CTC CTA GCT CTT CTC CAG GGA GGA-5' (456 bp). PCR was run under the following conditions: initial denaturation at 94 °C for 3 min, repeated denaturation at 94 °C for 45 s, followed with annealing at 66 °C for 45 s for CYP2E1 and 67 °C for 45 s for β -actin, primer extension at 72 °C for 45 s, and final extension at 72 °C for 3 min. The other conditions for RT-PCR were as described previously [17].

2.7. Preparation of microsomes

Tissue microsomes were prepared according to Yokogawa et al. [17] with slight modifications. Liver, kidney or abdominal fat was homogenized with phosphate buffer (50 mM K_2HPO_4 containing 0.1 mM EDTA, pH 7.4). The homogenate was centrifuged at $10,000 \times g$ for 30 min, and then the supernatant was recentrifuged at $100,000 \times g$ for 60 min. The microsomal pellet was collected, and resuspended in an appropriate volume of 50 mM Tris-acetate buffer (pH 7.4) containing 1 mM EDTA and 20% glycerol. The protein concentration of the microsomal solution was determined with a protein assay kit from Bio-Rad Laboratories Inc. (Hercules, CA).

2.8. Immunoblotting

Immunoblotting of the microsomes for CYP2E1 and β -actin was carried out essentially as described by Yokogawa et al. [18]. The microsomal protein was resolved by 10% SDS-PAGE, and transferred to a polyvinylidene fluoride membrane or Immobilon-P® (Millipore Co., Bedford, MA). The membrane was incubated with blocking buffer for 1 h (5%, w/v, non-fat dried milk in PBS), followed with overnight incubation in a 2000-fold dilution of primary antibody (goat anti-rat CYP2E1 from Daiichi, Pure Chemicals Co., Ltd., Tokyo, Japan, and goat anti-rat β -actin from Santa Cruz Biotechnology Inc., Santa

Cruz, CA). The membranes were then incubated with a 2000-fold dilution of secondary antibody (rabbit anti-goat IgG from Santa Cruz Biotechnology Inc., Santa Cruz, CA). The immunopositive band was detected with an ECL chemiluminescence detection kit (Amersham Biosciences UK Ltd., Buckinghamshire, UK), and scanned with a Typhoon 9200 scanner (Amersham Biosciences Europe GmbH, Freiburg, Germany).

2.9. Measurement of hydroxylation activity of microsomal CYP2E1

The enzyme activity of microsomal CYP2E1 was determined by the measurement of 6OHCZX formation according to Chittur and Tracy [19], with minor modifications. A mixture of the microsomal solution (equivalent to 0.4 mg protein) and 50 mM phosphate buffer (pH 7.4) containing 50 μ M CZX and 1 mM NADPH (final, 200 μ l) was incubated at 37 °C for appropriate times. The reaction was stopped by adding 100 μ l of acetonitrile containing phenacetin (1 μ g) as an internal standard for HPLC assay. The 6OHCZX formed was extracted with diethyl ether and measured by HPLC as described above.

2.10. Measurement of glucuronidation activity of microsomal UGTs

The activity of UDP-glucuronosyltransferase (UGT) in microsomes was measured colorimetrically in 0.15 M Tris-phosphate buffer pH 7.4 containing 0.8 mM *p*-nitrophenol (PNP), 14 mM UDP glucuronic acid, 10 mM $MgCl_2$, and 1 mg microsomal protein [20]. The mixture (1.4 ml) was incubated at 37 °C for 30 min, then the reaction was stopped by adding 5 ml of 0.2 M glycine buffer (pH 10.4). The disappearance of PNP was quantified in terms of absorbance at 405 nm with a UV-vis spectrophotometer. The microsomal activities for glucuronidation of CZX and 6OHCZX were assayed similarly, except that the disappearance of CZX and 6OHCZX was determined by HPLC.

Table 1 – Physical and biochemical data in rats with obesity

Parameters	Rats		
	ND	HF	OB
Physical data			
Body weight (g)	385 $\pm$ 5.0	410 $\pm$ 17.3	480 $\pm$ 8.3**
Liver (g)	5.94 $\pm$ 0.42	6.22 $\pm$ 0.64	11.85 $\pm$ 0.88**
Kidney (g)	2.11 $\pm$ 0.08	2.13 $\pm$ 0.14	2.23 $\pm$ 0.12
Epididymal fat (g)	3.49 $\pm$ 0.64	4.35 $\pm$ 1.12	12.74 $\pm$ 1.63**
Biochemical data			
Albumin (g/dl)	4.26 $\pm$ 0.23	4.30 $\pm$ 0.10	4.07 $\pm$ 0.06
T-bilirubin (mg/dl)	0.057 $\pm$ 0.006	0.057 $\pm$ 0.012	0.28 $\pm$ 0.030**
T-cholesterol (mg/dl)	75 $\pm$ 1.5	81 $\pm$ 2.1*	88 $\pm$ 1.5**
Creatinine (mg/dl)	0.29 $\pm$ 0.02	0.30 $\pm$ 0.02	0.31 $\pm$ 0.01
AST (IU/l)	81 $\pm$ 7.0	79 $\pm$ 3.1	83 $\pm$ 6.6
Cholinesterase (IU/l)	>4	>4	>4

Data were presented as mean $\pm$ S.D. of four rats. *Significant difference from ND rats at $P < 0.05$. **Significant difference from ND rats at $P < 0.01$.

Fig. 1 – Plasma concentration–time courses of CZX (closed symbols) and 6OHCZX-T (open symbols) after an i.v. administration of CZX (20 mg/kg) over 2 min in ND (○), HF (□) and OB (△) rats. The concentration of CZX is shown as unchanged fraction, while 6OHCZX is shown as total 6OHCZX (unchanged fraction plus glucuronidated fraction). Each point and bar represents the mean + S.D. of four rats. *Significant difference from ND rats at $P < 0.05$. **Significant difference from ND rats at $P < 0.01$.

2.11. Data analysis

The pharmacokinetic parameters were calculated according to model-independent moment analysis as described by Yamaoka et al. [21]. Electrophoregrams after RT-PCR and immunopositive bands were evaluated in arbitrary units by using NIH Image software. Comparisons of numerical data among groups were made by one-way ANOVA, with $P < 0.05$ as the criterion of a significant difference. For each significant effect, a multiple comparison test was performed with Scheffe's test to verify the difference between groups at P -values of 0.05 and 0.01, using SPSS 10[®] from SPSS Inc. (Chicago, IL).

3. Results

3.1. Physical and biochemical data

Table 1 summarizes the physical data for ND, HF and OB rats. The body, liver and epididymal fat weights of OB rats were significantly higher than those of ND rats. The fat tissue weight of HF rats, although slightly higher, was not significantly different from that of ND rats. The value of total bilirubin of OB rats was significantly higher than that of ND rats, but liver function (AST) and kidney function (creatinine) were unaffected. Total cholesterol was significantly increased in HF rats and OB rats compared with normal rats.

3.2. Disposition kinetics of CZX

Fig. 1 shows the plasma concentration–time courses of CZX and 6OHCZX after an i.v. administration of CZX 20 mg/kg in ND, HF and OB rats. The plasma concentrations of CZX linearly decreased in all cases, but the concentration at 8 h after administration was in the order of $ND > HF > OB$ rats. In this figure, the concentration of 6OHCZX is presented as a total value of 6OHCZX (6OHCZX-T), i.e., the sum of free 6OHCZX and glucuronidated 6OHCZX, after the administration of CZX. The amount of the glucuronide conjugate of CZX (CZX-G) was negligible (data not shown). It was found that the plasma concentration of 6OHCZX-T increased gradually and reached a peak at about 2 h after administration. The peak concentration of 6OHCZX-T in OB rats was significantly higher than that in ND rats. Table 2 shows the pharmacokinetic parameters of CZX and 6OHCZX-T after administration of CZX 20 mg/kg. In OB rats, the AUC_{∞} , $T_{1/2}$ and MRT values of CZX were significantly smaller, while the CL_{tot} and Vd_{ss} values of CZX were significantly larger than those of ND rats. The pharmacokinetic parameters in HF rats were intermediate between those in OB rats and ND rats. Moreover, the AUC_{∞} values of 6OHCZX-T in HF and OB rats were significantly higher than that of ND rats.

Table 2 – Pharmacokinetic parameters of CZX and 6OHCZX after an i.v. administration of CZX 20 mg/kg over 2 min

Parameters	Rats		
	ND	HF	OB
CZX			
AUC_{∞} (µg/h/ml) ^a	204 ± 14	181 ± 12	155 ± 21**
$T_{1/2}$ (h) ^b	1.67 ± 0.18	1.38 ± 0.19	1.19 ± 0.23*
MRT (h) ^c	2.40 ± 0.19	2.30 ± 0.28	2.00 ± 0.17*
CL_{tot} (l/h/kg) ^d	0.104 ± 0.002	0.122 ± 0.010*	0.145 ± 0.013**
Vd_{ss} (l/h) ^e	0.239 ± 0.014	0.277 ± 0.014**	0.285 ± 0.016**
6OHCZX-T			
AUC_{∞} (µg/h/ml)	41.2 ± 4.7	60.3 ± 4.2**	71.6 ± 5.9**

Data were presented as mean ± S.D. of four rats. *Significant difference from ND rats at $P < 0.05$. **Significant difference from ND rats at $P < 0.01$.

^a AUC from 0 to ∞ .
^b Half life.
^c Mean residence time.
^d Total clearance.
^e Volume of distribution at steady state.

Fig. 2 – Tissue and plasma concentrations of CZX and its glucuronide (CZX-G) at 4 h after an i.v. administration of CZX (20 mg/kg) over 2 min in ND (□), HF (▨) and OB (▩) rats. Each column and bar represents the mean + S.D. of four rats. *Significant difference from ND rats at $P < 0.05$. **Significant difference from ND rats at $P < 0.01$.

Fig. 2 shows the tissue concentration of CZX compared with the plasma concentration at 4 h after the i.v. administration of CZX. The CZX concentration in fat tissue was considerably higher than those of plasma, kidney and liver. The concentration of CZX-G was higher in HF rats and OB rats than ND rats. Fig. 3 shows the tissue concentrations of 6OHCZX and its glucuronide in fat, liver and kidney at 4 h after the i.v. administration of CZX. The concentrations of both 6OHCZX and 6OHCZX-G in plasma and all tissues tended to be higher in the HF rats and OB rats than those in the ND rats. Interestingly, the kidney concentration was much higher than those of other tissues, and the concentration of 6OHCZX-G in kidney of OB rats was significantly higher than that of ND rats.

3.3. Expression of CYP isoform mRNAs and proteins

The mRNA expression of CYP2E1 in liver of HF rats and OB rats was only slightly higher than that in ND rats, whereas, the relative expression of CYP2E1/ β -actin in fat tissue from HF rats and OB rats was apparently higher than that in ND rats (Fig. 4).

Fig. 3 – Tissue and plasma concentrations of 6OHCZX (6OH) and its glucuronide (6OH-G) at 4 h after an i.v. administration of CZX (20 mg/kg) over 2 min in ND (□), HF (▨) and OB (▩) rats. Each column and bar represents the mean + S.D. of four rats. *Significant difference from ND rats at $P < 0.05$. **Significant difference from ND rats at $P < 0.01$.

Fig. 4 – Effect of obesity on the expression of CYP2E1 mRNA compared with β -actin in liver, kidney and fat of ND (□), HF (▨) and OB (▩) rats. Each column and bar represents the mean + S.D. of four rats. *Significant difference from ND rats at $P < 0.05$. **Significant difference from ND rats at $P < 0.01$.

The expression levels of CYP2E1 protein in the liver, kidney and fat tissue were examined by immunoblot analysis. The protein levels of CYP2E1 in the liver and fat of HF rats and OB rats were conspicuously increased compared with those of ND rats. Furthermore, the relative expression of CYP2E1/ β -actin in liver microsomes and fat microsomes of HF and OB rats was significantly higher than that in ND rats (Fig. 5).

3.4. In vitro CYP2E1 and UGTs activity

Fig. 6 shows the hydroxylation activity of microsomal CYP2E1 in terms of 6OHCZX formation from CZX, in various tissues from the three groups of rats. The highest hydroxylation rate was found in the liver compared with kidney and fat tissue. The activities in liver and fat from HF rats and OB rats were significantly higher than those in ND rats, whereas, no difference was seen in the kidney.

Fig. 7 shows the glucuronidation activity of microsomal UGTs in liver and kidney towards PNP, CZX and 6OHCZX. The glucuronidation rates in the kidney of HF rats and OB rats were generally significantly higher than those in ND rats. The glucuronidation activity in fat was negligible in all groups. Interestingly, the glucuronidation of CZX was very much lower than that of 6OHCZX, although the enzyme activity in the liver was not affected by obesity.

4. Discussion

Zucker (*fa/fa*) rats at 20 weeks of age showed markedly increased body weight, accompanied with an enlarged liver and increased epididymal fat, compared with Zucker (*+/+*) rats. In contrast, Zucker (*+/+*) rats fed with high-fat diet (twice the level in normal diet) for 12 weeks did not show any significant physical or biochemical changes (Table 1).

CZX is well known to be a specific probe for CYP2E1, being hydroxylated to 6OHCZX [10,11], which in turn is rapidly glucuronidated to 6OHCZX-G [13]. Therefore, the appropriate

Fig. 5 – Effect of obesity on the content of CYP2E1 protein compared with β -actin in liver, kidney and fat of ND (□), HF (▨) and OB (▩) rats. Each column and bar represents the mean + S.D. of three rats. *Significant difference from ND rats at $P < 0.05$. **Significant difference from ND rats at $P < 0.01$.

Fig. 7 – Effect of obesity on the glucuronidation activity of microsomal UGTs in liver and kidney of ND (□), HF (▨) and OB (▩) rats. Each column and bar represents the mean + S.D. of four rats. *Significant difference from ND rats at $P < 0.05$. **Significant difference from ND rats at $P < 0.01$.

indicator for determining CYP2E1 activity in vivo should be the total amount of 6OHCZX generated after the administration of CZX, as reported in Fig. 1 and Table 2. The limited sampling time course of 8 h post-administration was contributed to the detection limits of both CZX and 6OHCZX. Most of 6OHCZX in biological samples were lower than the detection limit, and some of CZX levels were under the linearity of calibration curves at 12 h after administration of CZX. The administration of CZX 20 mg/kg to OB rats afforded lower values of AUC_{∞} and $T_{1/2}$ in serum as compared with those in ND rats, while the values of CL_{tot} and Vd_{ss} were significantly higher (Table 2). Based on the Vd_{ss} and the tissue concentration of CZX (Fig. 2), it appears that lipophilic substances, such as CZX, penetrate well into the fat reservoirs of OB rats. The fat to plasma ratio of CZX was two to four folds both at 1 and 4 h of tissue sampling time, and the OB rats showed the higher trend of accumulation (data not shown for 1 h). Therefore, if CYP2E1 were not induced in the fat of OB rats, it is likely that the elimination rate of CZX would be delayed. However, the $T_{1/2}$ of CZX in OB rats was shorter than in ND rats, and further, the value of

Fig. 6 – Effect of obesity on the hydroxylation activity of microsomal CYP2E1 in liver, kidney and fat of ND (□), HF (▨) and OB (▩) rats. Each column and bar represents the mean + S.D. of four rats. *Significant difference from ND rats at $P < 0.05$. **Significant difference from ND rats at $P < 0.01$.

6OHCZX in fat higher than the plasma level (Fig. 3). It is unlikely that 6OHCZX from blood would accumulate in fat, because 6OHCZX is relatively hydrophilic and is rapidly glucuronidated by UGTs located in smooth endoplasmic reticulum, the same location as that of CYP2E1 [22]. Therefore, the induction of CYP2E1 in fat, in addition to liver, may play a pivotal role in determining the disposition kinetics of CZX in obese rats. We also found that the AUC_{∞} ratio of 6OHCZX-T/CZX in HF rats and OB rats was 1.5–2 times higher than that in ND rats, reflecting the increased total activity of CYP2E1 in rats with obesity. Lucas et al. [7] reported that the 6OHCZX-T/CZX ratio (0.4) in obese or hyperlipidemic patients was higher than that (0.3) in normal subjects, in agreement with our finding. These results suggest that obesity and feeding of a high-fat diet can induce CYP2E1 activity in both humans and rats.

We found that both the protein content and activity of CYP2E1 were increased in microsomes of the liver from HF rats and OB rats, while there was no change in the kidney. Kobayashi et al. [23] reported that CZX was extensively metabolized in rat microsomes not only by CYP2E1, but also by CYP1A2 and CYP3A. Therefore, we also examined the mRNA expression and protein content of CYP1A2 and CYP3A, but found that they were unaffected by obese status (data not shown). Enriquez et al. and Irizar et al. [24,6] reported that CYP2E is poorly expressed in obese Zucker rats, which is consistent with our finding. However, Enriquez et al. [24] reported that CZX hydroxylase activity and CYP2E1 protein content were lower in Zucker (*fa/fa*) rats than in lean (+/?) littermates. There are various differences between their experimental conditions and ours, but one of the most important factors could be the influence of aging in obese Zucker (*fa/fa*) rats. Young obese Zucker (*fa/fa*) rats do not exhibit pathological conditions such as physical obesity, insulin resistance, etc., and usually have a lower CYP2E1 activity than their lean littermates, whereas, after the appearance of pathological symptoms at approximately 14–16 weeks of age, expression of CYP2E1 is increased. Therefore, we used Zucker (*fa/fa*) rats at 20 weeks of age in our study, when their pathological condition appeared to resemble that of severe obesity in humans. The report by Enriquez et al. [24]

did not mention the physical condition of either the lean or obese Zucker rats, so that it is difficult to compare their findings and ours. Interestingly, the CYP2E1 mRNA isoform was expressed in fat tissue, and its expression level and activity were significantly higher in HF rats and OB rats than in ND rats (Figs. 4–6). Yoshinari et al. [25] and Wan et al. [26] reported that the expression levels of both CYP2E1 mRNA and protein were increased in adipose tissue of fasting rats. However, the amount of adipose tissue in fasting rats was small, and so CYP2E1 in fasting animals may contribute little to the pharmacokinetics of its substrates compared with the situation in obese animals.

The hydroxylated metabolite of CZX (6OHCZX) has been reported to be excreted in bile to only a small extent; rather it undergoes rapid glucuronidation with subsequent excretion of the conjugate in urine [13]. We found that the glucuronidation activity in kidney microsomes was significantly higher in HF rats and OB rats than ND rats (Fig. 7), and the concentration of 6OHCZX glucuronide in the kidney was higher than that in the liver (Fig. 3). Since there is no evidence that a specific UGT subfamily involved in glucuronide conjugation of CZX and 6OHCZX, we used PNP, a general marker for glucuronidation, to confirm our results. The glucuronidation activity towards PNP in kidney microsomes of HF and OB rats showed the same trend as did the activity towards CZX and 6OHCZX. However, the glucuronidation activity in liver microsomes was not influenced by the high-fat diet or obese status, and was quite different towards different substrates. This suggests the presence of different UGTs isoforms in liver and kidney. Further research will be required to identify the UGTs isoform(s) responsible for 6OHCZX glucuronidation in tissues, and the species that are affected by obese status.

In conclusion, CYP2E1 activity was induced in the liver fat tissues of obese animals, and glucuronidation activity were induced in the kidney. As a result, the disposition kinetics of CZX was markedly changed in obesity, with an increase in hydroxylation of CZX to form 6OHCZX, and an acceleration of 6OHCZX glucuronidation, resulting in rapid excretion in urine. Other drugs that are metabolized by CYP2E1 and UGTs may show similar changes of disposition kinetics in obese patients, resulting in reduced potency and shorter duration of action.

REFERENCES

- [1] Chopra M, Galbraith S, Darnton-Hill I. A global response to a global problem: the epidemic of overnutrition. *Bull WHO* 2002;80:952–8.
- [2] WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity, Geneva, Switzerland, June 3–5 1997. Division of Noncommunicable Disease, 1998. p. 17–40.
- [3] Ingvarsen KL, Boisclair YR. Leptin and the regulation of food intake, energy homeostasis and immunity with special focus on periparturient ruminants. *Domest Anim Endocrinol* 2001;21:215–50.
- [4] Sone M, Osamura RY. Leptin and the pituitary. *Pituitary* 2001;4:15–23.
- [5] Bahceci M, Tuzcu A, Akkus M, Yaldiz M, Ozbay A. The effect of high-fat diet on the development of obesity and serum leptin level in rats. *Eat Weight Disord* 1999;4:128–32.
- [6] Irizar A, Barnett CR, Flatt PR, Ioannides C. Defective expression of cytochrome P450 proteins in the liver of the genetically obese Zucker rat. *Eur J Pharmacol* 1995;293:385–93.
- [7] Lucas D, Farez C, Bardou LG, Vaisse J, Attali JR, Valensi P. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. *Fundam Clin Pharmacol* 1998;12:553–8.
- [8] O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. *Clin Pharmacol Ther* 1994;56:359–67.
- [9] Raucy JL, Lasker JM, Kraner JC, Salazar DE, Lieber CS, Corcoran GB. Induction of cytochrome P450IIE1 in the obese overfed rat. *Mol Pharmacol* 1991;39:275–80.
- [10] Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. *Chem Res Toxicol* 1990;3:566–73.
- [11] Rockich K, Blouin R. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats. *Drug Metab Dispos* 1999;27:1074–7.
- [12] Conney AH, Burns JJ. Physiological disposition and metabolic fate of chlorzoxazone (Paraflex) in man. *J Pharmacol Exp Ther* 1960;128:340–3.
- [13] Mehvar R, Vupputgalla R. Hepatic disposition of the cytochrome P450 2E1 marker chlorzoxazone and its hydroxylated metabolite in isolated perfused rat livers. *J Pharm Sci* 2006;95:1414–24.
- [14] Moffat AC, Osselton MD, Widdop B. Chlorzoxazone. In: Moffat AC, Osselton MD, Widdop B, Galichet LY, editors. 3rd ed., *Clarke's Analysis of Drugs and Poisons*, vol. II, 3rd ed. London: Pharmaceutical Press; 2004. p. 797–8.
- [15] Frye RF, Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1996;686:291–6.
- [16] Court MH, Von Moltke LL, Shader RI, Greenblatt DJ. Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. *Biopharm Drug Dispos* 1997;18:213–26.
- [17] Yokogawa K, Watanabe M, Takeshita H, Nomura M, Mano Y, Miyamoto K. Serum aminotransferase activity as a predictor of clearance of drugs metabolized by CYP isoforms in rats with acute hepatic failure induced by carbon tetrachloride. *Int J Pharm* 2004;269:479–89.
- [18] Yokogawa K, Shimada T, Higashi Y, Itoh Y, Masue T, Ishizaki J, et al. Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone. *Biochem Pharmacol* 2002;63:777–83.
- [19] Chittur SV, Tracy TS. Rapid and sensitive high-performance liquid chromatographic assay for 6-hydroxychlorzoxazone and chlorzoxazone in liver microsomes. *J Chromatogr B Biomed Sci Appl* 1997;693:479–83.
- [20] Lucier GW, Sonawane BR, McDaniel OS. Glucuronidation and deglucuronidation reactions in hepatic and extrahepatic tissues during perinatal development. *Drug Metab Dispos* 1977;5:279–87.
- [21] Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. *J Pharm Biopharm* 1978;6:547–58.
- [22] Parkinson A. Biotransformation of xenobiotics. In: Klaassen CD, editor. *Casarett and Doull's toxicology: the basic science of poisons*. 5th ed., New York: McGraw-Hill; 1996. p. 163–8.
- [23] Kobayashi K, Urashima K, Shimada N, Chiba K. Substrate specificity for rat cytochrome P450 (CYP) isoforms:

- 482 screening with cDNA-expressed systems of the rat. 488
483 Biochem Pharmacol 2002;63:889–96. 489
484 [24] Enriquez A, Leclercq I, Farrell GC, Robertson G. Altered 490
485 expression of hepatic CYP2E1 and CYP4A in obese, diabetic 491
486 ob/ob mice, and fa/fa Zucker rats. Biochem Biophys Res 492
487 Commun 1999;255:300–6. 493
494 [25] Yoshinari K, Sato T, Okino N, Sugatani J, Miwa M. 488
Expression and induction of cytochromes P450 in rat white 489
adipose tissue. J Pharmacol Exp Ther 2004;311:147–54. 490
[26] Wan J, Ernstgard L, Song BJ, Shoaf SE. Chlorzoxazone 491
metabolism is increased in fasted Sprague–Dawley rats. J 492
Pharm Pharmacol 2006;58:51–61. 493
494

UNCORRECTED PROOF